References
- Wani M C, Taylor H L, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and anti-tumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–2329
- Schiff P B, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature (London) 1979; 277: 665–667
- Schiff P B, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci (USA) 1980; 77: 1561–1565
- Kris M G, O'Connell J P, Gralla RJ, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605–607
- Longnecker S M, Donehower R C, Cates AE, et al. High-performance liquid chromotographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–59
- Donehower R C, Rowinsky E K, Grochow LB, et al. Phase I Trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171–1177
- Grem J L, Tutsch K D, Simon KJ, et al. Phase I Study of Taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179–1184
- Wiernik P H, Schwartz E L, Strauman JJ, et al. Phase I Clinical and Pharmacokinetic Study of Taxol. Cancer Res 1987; 47: 2486–2493
- Ohnuma T, Zimet A S, Coffey VA, et al. Phase I study of taxol in a 24-h infusion schedule. Proc Am Assoc Cancer Res 1985; 26: 167, abstr
- Legha S, Tenney D M, Krokoff IR. A Phase I study of Taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4: 762–766
- Wiernik P H, Schwartz E L, Einzig A, et al. Phase I Trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232–1239
- Hrushesky W J, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977; 9: 277–288
- Talley RW. Chemotherapy of adenocarcinoma of the kidney. Cancer 1973; 32: 1062
- Woodruff N N, Nagle D, Gailoni SD, et al. The current status of chemotherapy of advanced renal cell carcinoma. J Urol 1967; 97: 611
- McDonald MN. Current therapy for renal cell carcinoma. J Urol 1982; 127: 211
- Oken M M, Creech R H, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655